Trade Biomerieux - BIM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.40 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.021388% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.000834% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | France | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Biomerieux SA ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 88.65 |
| Open* | 88.95 |
| 1-Year Change* | 9.01% |
| Day's Range* | 88.05 - 88.95 |
| 52 wk Range | 77.48-104.00 |
| Average Volume (10 days) | 119.27K |
| Average Volume (3 months) | 1.72M |
| Market Cap | 10.97B |
| P/E Ratio | 28.46 |
| Shares Outstanding | 118.12M |
| Revenue | 3.70B |
| EPS | 3.26 |
| Dividend (Yield %) | 0.91753 |
| Beta | 0.04 |
| Next Earnings Date | Mar 6, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 27, 2023 | 88.65 | -1.00 | -1.12% | 89.65 | 90.45 | 88.55 |
| Sep 26, 2023 | 89.85 | 0.15 | 0.17% | 89.70 | 90.40 | 88.55 |
| Sep 25, 2023 | 90.35 | 0.10 | 0.11% | 90.25 | 90.65 | 89.55 |
| Sep 22, 2023 | 90.65 | 2.15 | 2.43% | 88.50 | 91.10 | 88.50 |
| Sep 21, 2023 | 89.85 | -1.60 | -1.75% | 91.45 | 91.80 | 89.85 |
| Sep 20, 2023 | 92.40 | 2.10 | 2.33% | 90.30 | 92.60 | 90.30 |
| Sep 19, 2023 | 90.05 | -0.80 | -0.88% | 90.85 | 91.15 | 89.65 |
| Sep 18, 2023 | 91.35 | 0.15 | 0.16% | 91.20 | 92.65 | 90.80 |
| Sep 15, 2023 | 91.20 | -1.40 | -1.51% | 92.60 | 93.50 | 90.90 |
| Sep 14, 2023 | 92.55 | 1.35 | 1.48% | 91.20 | 93.05 | 91.20 |
| Sep 13, 2023 | 91.50 | 1.70 | 1.89% | 89.80 | 91.50 | 89.10 |
| Sep 12, 2023 | 90.25 | -1.20 | -1.31% | 91.45 | 92.00 | 90.25 |
| Sep 11, 2023 | 91.80 | 0.00 | 0.00% | 91.80 | 92.55 | 90.85 |
| Sep 8, 2023 | 91.95 | -0.55 | -0.59% | 92.50 | 92.85 | 91.25 |
| Sep 7, 2023 | 92.30 | 1.10 | 1.21% | 91.20 | 92.55 | 90.90 |
| Sep 6, 2023 | 91.70 | -1.60 | -1.71% | 93.30 | 93.45 | 90.65 |
| Sep 5, 2023 | 94.15 | -0.95 | -1.00% | 95.10 | 95.80 | 93.70 |
| Sep 4, 2023 | 95.40 | 0.85 | 0.90% | 94.55 | 96.45 | 94.55 |
| Sep 1, 2023 | 94.40 | -0.10 | -0.11% | 94.50 | 94.65 | 88.05 |
| Aug 31, 2023 | 96.20 | -1.00 | -1.03% | 97.20 | 97.70 | 95.65 |
Biomerieux Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, October 26, 2023 | ||
| Time (UTC) 06:30 | Country FR
| Event Q3 2023 Biomerieux SA Corporate Sales Release Q3 2023 Biomerieux SA Corporate Sales ReleaseForecast -Previous - |
| Time (UTC) 10:59 | Country FR
| Event Q3 2023 Biomerieux SA Corporate Sales Call Q3 2023 Biomerieux SA Corporate Sales CallForecast -Previous - |
| Wednesday, March 6, 2024 | ||
| Time (UTC) 07:30 | Country FR
| Event Full Year 2023 Biomerieux SA Earnings Release Full Year 2023 Biomerieux SA Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 3589.1 | 3376.2 | 3118.2 | 2674.8 | 2421.3 |
| Revenue | 3589.1 | 3376.2 | 3118.2 | 2674.8 | 2421.3 |
| Cost of Revenue, Total | 1580.4 | 1375.4 | 1364.5 | 1208.2 | 1119 |
| Gross Profit | 2008.7 | 2000.8 | 1753.7 | 1466.6 | 1302.3 |
| Total Operating Expense | 3001.9 | 2591.3 | 2566 | 2304.1 | 2075.2 |
| Selling/General/Admin. Expenses, Total | 954.7 | 815.6 | 789.3 | 749.8 | 643.1 |
| Research & Development | 446.6 | 385.8 | 398.8 | 374.3 | 326.9 |
| Depreciation / Amortization | 76.6 | 59.7 | 17.5 | 17.9 | 17.5 |
| Unusual Expense (Income) | -0.6 | 0.6 | |||
| Other Operating Expenses, Total | -56.4 | -44.6 | -4.7 | -46.1 | -31.3 |
| Operating Income | 587.2 | 784.9 | 552.2 | 370.7 | 346.1 |
| Interest Income (Expense), Net Non-Operating | -4.3 | -11.7 | -29.1 | -23.8 | -26.7 |
| Other, Net | -2.3 | 1.3 | 1.2 | 0.7 | -1.9 |
| Net Income Before Taxes | 580.6 | 774.5 | 524.3 | 347.6 | 317.5 |
| Net Income After Taxes | 440.5 | 598.9 | 402.8 | 269.8 | 252.4 |
| Minority Interest | 11.8 | 2.9 | 1.7 | 3.1 | 1.1 |
| Equity In Affiliates | 0 | -0.7 | -0.2 | 0 | 0.2 |
| Net Income Before Extra. Items | 452.3 | 601.1 | 404.3 | 272.9 | 253.7 |
| Net Income | 452.3 | 601.1 | 404.3 | 272.9 | 253.7 |
| Total Adjustments to Net Income | 0.1 | 0 | 0.1 | -0.1 | 2.8 |
| Income Available to Common Excl. Extra. Items | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
| Income Available to Common Incl. Extra. Items | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
| Diluted Net Income | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
| Diluted Weighted Average Shares | 118.441 | 118.893 | 118.592 | 118.609 | 118.203 |
| Diluted EPS Excluding Extraordinary Items | 3.81964 | 5.05579 | 3.41 | 2.3 | 2.17 |
| Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.62 | 0.19 | 0.35 |
| Diluted Normalized EPS | 3.81964 | 5.05189 | 3.41389 | 2.3 | 2.17 |
| Dilution Adjustment | 0 |
| Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
|---|---|---|---|---|
| Total revenue | 1931.1 | 1658 | 1802 | 1574.2 |
| Revenue | 1931.1 | 1658 | 1802 | 1574.2 |
| Cost of Revenue, Total | 860.4 | 720 | 721.6 | 659.2 |
| Gross Profit | 1070.7 | 938 | 1080.4 | 915 |
| Total Operating Expense | 1641 | 1360.9 | 1383.5 | 1208.4 |
| Selling/General/Admin. Expenses, Total | 514.4 | 440.3 | 436.9 | 379.6 |
| Research & Development | 239.3 | 207.3 | 204.8 | 181.5 |
| Depreciation / Amortization | 51.7 | 24.9 | 44.6 | 8.3 |
| Other Operating Expenses, Total | -24.8 | -31.6 | -24.4 | -20.2 |
| Operating Income | 290.1 | 297.1 | 418.5 | 365.8 |
| Interest Income (Expense), Net Non-Operating | 2.8 | -7.1 | -4.7 | -7 |
| Other, Net | -3.8 | 1.5 | 1.3 | 0.6 |
| Net Income Before Taxes | 289.1 | 291.5 | 415.1 | 359.4 |
| Net Income After Taxes | 214.2 | 226.3 | 322 | 276.9 |
| Minority Interest | 10 | 1.8 | 1.8 | 1.1 |
| Equity In Affiliates | 0 | 0 | 0.2 | -0.9 |
| Net Income Before Extra. Items | 224.2 | 228.1 | 324 | 277.1 |
| Net Income | 224.2 | 228.1 | 324 | 277.1 |
| Income Available to Common Excl. Extra. Items | 224.4 | 228 | 324 | 277.1 |
| Income Available to Common Incl. Extra. Items | 224.4 | 228 | 324 | 277.1 |
| Diluted Net Income | 224.4 | 228 | 324 | 277.1 |
| Diluted Weighted Average Shares | 118.533 | 118.349 | 119.1 | 118.927 |
| Diluted EPS Excluding Extraordinary Items | 1.89315 | 1.92651 | 2.7204 | 2.33 |
| Dividends per Share - Common Stock Primary Issue | 0.85 | 0 | 0.85 | 0 |
| Diluted Normalized EPS | 1.89315 | 1.92651 | 2.7204 | 2.33 |
| Total Adjustments to Net Income | 0.2 | -0.1 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 2216.7 | 2184.6 | 1661.6 | 1438.5 | 1314.4 |
| Cash and Short Term Investments | 552.6 | 803.5 | 389.2 | 275 | 288.3 |
| Cash | 552.6 | 803.5 | 313.5 | 241 | 239.9 |
| Cash & Equivalents | 75.7 | 34 | 48.4 | ||
| Total Receivables, Net | 926.9 | 761 | 730.4 | 668.8 | 607.3 |
| Accounts Receivable - Trade, Net | 740.1 | 590.6 | 597.9 | 552.1 | 491.8 |
| Total Inventory | 737.2 | 620 | 541.9 | 494.7 | 418.8 |
| Other Current Assets, Total | 0.1 | 0.1 | |||
| Total Assets | 5186.6 | 4605 | 3927.8 | 3781.9 | 3501.6 |
| Property/Plant/Equipment, Total - Net | 1369.9 | 1224.8 | 1068.6 | 1025.2 | 899.1 |
| Property/Plant/Equipment, Total - Gross | 2703.9 | 2447.7 | 2173.3 | 2100.9 | 1899.4 |
| Accumulated Depreciation, Total | -1334.1 | -1222.7 | -1104.7 | -1075.7 | -1000.5 |
| Goodwill, Net | 812.5 | 669.5 | 629.4 | 652.5 | 619 |
| Intangibles, Net | 625 | 411.5 | 430.7 | 508.4 | 507.2 |
| Long Term Investments | 71.2 | 62 | 39.9 | 31.7 | 59.2 |
| Note Receivable - Long Term | 19.8 | 10.7 | 10.4 | 8 | |
| Other Long Term Assets, Total | 71.5 | 52.6 | 86.9 | 115.2 | 94.7 |
| Total Current Liabilities | 1131.1 | 955.7 | 923.8 | 1170.1 | 796.3 |
| Accounts Payable | 269.4 | 239.5 | 207.1 | 211.9 | 179.7 |
| Accrued Expenses | 372.6 | 327.4 | 283.3 | 262.4 | |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 187 | 99.7 | 128.9 | 438.6 | 129.1 |
| Other Current Liabilities, Total | 302.1 | 616.5 | 260.4 | 236.3 | 225.1 |
| Total Liabilities | 1582.4 | 1492.8 | 1496.7 | 1578 | 1572.8 |
| Total Long Term Debt | 318.4 | 362.8 | 352.4 | 153.7 | 524.9 |
| Long Term Debt | 318.4 | 362.8 | 352.4 | 153.7 | 524.9 |
| Deferred Income Tax | 53 | 60.3 | 105.8 | 141.2 | 130.5 |
| Minority Interest | 38.7 | 51.4 | 50.2 | 50.7 | 74.1 |
| Other Liabilities, Total | 41.2 | 62.6 | 64.5 | 62.3 | 47 |
| Total Equity | 3604.2 | 3112.2 | 2431.1 | 2203.9 | 1928.8 |
| Common Stock | 12 | 12 | 12 | 12 | 12 |
| Additional Paid-In Capital | 3062.2 | 2532.1 | 2204.7 | 1933.4 | 1712.2 |
| Retained Earnings (Accumulated Deficit) | 410.4 | 542.5 | 344.7 | 207.9 | 210.1 |
| Treasury Stock - Common | -36 | -10.3 | -23 | -3.9 | -32.8 |
| Other Equity, Total | 155.6 | 35.9 | -107.3 | 54.5 | 27.3 |
| Total Liabilities & Shareholders’ Equity | 5186.6 | 4605 | 3927.8 | 3781.9 | 3501.6 |
| Total Common Shares Outstanding | 118 | 118.282 | 118.16 | 118.324 | 117.819 |
| Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
|---|---|---|---|---|
| Total Current Assets | 2216.7 | 2058.4 | 2184.6 | 1798.7 |
| Cash and Short Term Investments | 552.6 | 524.2 | 803.5 | 493.2 |
| Cash | 552.6 | 524.2 | 803.5 | 363.3 |
| Cash & Equivalents | 129.9 | |||
| Total Receivables, Net | 926.9 | 825.7 | 761 | 694.5 |
| Accounts Receivable - Trade, Net | 740.1 | 624.2 | 590.6 | 542.4 |
| Total Inventory | 737.2 | 708.5 | 620 | 611 |
| Total Assets | 5186.6 | 5041.2 | 4605 | 4157.2 |
| Property/Plant/Equipment, Total - Net | 1369.9 | 1314.4 | 1224.8 | 1135.2 |
| Property/Plant/Equipment, Total - Gross | 2703.9 | 2620.7 | 2447.7 | 2306.1 |
| Accumulated Depreciation, Total | -1334 | -1306.2 | -1222.7 | -1170.8 |
| Goodwill, Net | 812.5 | 877.5 | 669.5 | 642.4 |
| Intangibles, Net | 625 | 667.5 | 411.5 | 426.8 |
| Long Term Investments | 91 | 48 | 62 | 56.6 |
| Other Long Term Assets, Total | 71.5 | 75.4 | 52.6 | 97.5 |
| Total Current Liabilities | 1131.1 | 1020.7 | 955.7 | 857.9 |
| Accounts Payable | 269.4 | 243.4 | 239.5 | 199.1 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 187 | 226 | 99.7 | 163.2 |
| Other Current Liabilities, Total | 674.7 | 551.3 | 616.5 | 495.6 |
| Total Liabilities | 1582.4 | 1572.2 | 1492.8 | 1459 |
| Total Long Term Debt | 318.4 | 365.7 | 362.8 | 361.5 |
| Long Term Debt | 318.4 | 365.7 | 362.8 | 361.5 |
| Deferred Income Tax | 53 | 97.2 | 60.3 | 124.7 |
| Minority Interest | 38.7 | 44.9 | 51.4 | 50.8 |
| Other Liabilities, Total | 41.2 | 43.7 | 62.6 | 64.1 |
| Total Equity | 3604.2 | 3469 | 3112.2 | 2698.2 |
| Common Stock | 12 | 12.2 | 12 | 12 |
| Additional Paid-In Capital | 3062.2 | 3174.3 | 2532.1 | 2528.8 |
| Retained Earnings (Accumulated Deficit) | 410.4 | 183.5 | 542.5 | 219.5 |
| Treasury Stock - Common | -36 | -152.3 | -10.3 | -16.6 |
| Other Equity, Total | 155.6 | 251.3 | 35.9 | -45.5 |
| Total Liabilities & Shareholders’ Equity | 5186.6 | 5041.2 | 4605 | 4157.2 |
| Total Common Shares Outstanding | 118 | 119.507 | 118.282 | 118.095 |
| Other Current Assets, Total | 0.1 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 440.5 | 598.2 | 402.7 | 269.7 | 255.6 |
| Cash From Operating Activities | 475.1 | 824.7 | 582.8 | 407.9 | 399.7 |
| Cash From Operating Activities | 67 | 58.8 | 210.8 | 189.5 | 177 |
| Non-Cash Items | 264.8 | 176.7 | 159 | 45.5 | 12.3 |
| Cash Taxes Paid | 223.5 | 185.4 | 115.9 | 81.6 | 66.5 |
| Cash Interest Paid | |||||
| Changes in Working Capital | -297.2 | -9 | -189.7 | -96.8 | -45.2 |
| Cash From Investing Activities | -528.1 | -307.3 | -265.2 | -282.2 | -413.1 |
| Capital Expenditures | -286.7 | -290.1 | -277.5 | -272.5 | -226.4 |
| Other Investing Cash Flow Items, Total | -241.4 | -17.2 | 12.3 | -9.7 | -186.7 |
| Cash From Financing Activities | -244.2 | -140.6 | -176.2 | -133.9 | 43 |
| Financing Cash Flow Items | -0.1 | -2.4 | -23.4 | 0 | |
| Total Cash Dividends Paid | -101.2 | -73.1 | -22.5 | -41.3 | -40.2 |
| Issuance (Retirement) of Stock, Net | -157.2 | -17.4 | -16.8 | 0 | -22.3 |
| Issuance (Retirement) of Debt, Net | 14.3 | -50.1 | -134.5 | -69.2 | 105.5 |
| Foreign Exchange Effects | 38.7 | 39.2 | -34.1 | -6.1 | -11.8 |
| Net Change in Cash | -258.5 | 416 | 107.3 | -14.3 | 17.8 |
| Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
|---|---|---|---|---|
| Net income/Starting Line | 440.5 | 226.2 | 598.2 | 276 |
| Cash From Operating Activities | 475.1 | 150.9 | 824.7 | 285.8 |
| Cash From Operating Activities | 67 | 100.4 | 58.8 | 97.2 |
| Non-Cash Items | 264.8 | -27.4 | 176.7 | -66.4 |
| Cash Taxes Paid | 223.5 | 145.4 | 185.4 | 98.1 |
| Changes in Working Capital | -297.2 | -148.3 | -9 | -21 |
| Cash From Investing Activities | -528.1 | -352.3 | -307.3 | -143.4 |
| Capital Expenditures | -286.7 | -152.8 | -290.1 | -143.5 |
| Other Investing Cash Flow Items, Total | -241.4 | -199.5 | -17.2 | 0.1 |
| Cash From Financing Activities | -244.2 | -127.8 | -140.6 | -73.8 |
| Total Cash Dividends Paid | -101.2 | -101.2 | -73.1 | -73.1 |
| Issuance (Retirement) of Stock, Net | -157.2 | -111.3 | -17.4 | -2.5 |
| Issuance (Retirement) of Debt, Net | 14.3 | 84.8 | -50.1 | 1.8 |
| Foreign Exchange Effects | 38.7 | 55.2 | 39.2 | 12.8 |
| Net Change in Cash | -258.5 | -274 | 416 | 81.4 |
| Financing Cash Flow Items | -0.1 | -0.1 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Mérieux Family | Other Insider Investor | 58.9047 | 69720270 | 0 | 2022-12-13 | |
| Dassault Family | Other Insider Investor | 4.5964 | 5440410 | 0 | 2022-12-13 | LOW |
| Sofina S.A. | Investment Advisor/Hedge Fund | 1.7293 | 2046857 | 0 | 2022-12-13 | LOW |
| Oddo BHF Asset Management S.A.S | Investment Advisor/Hedge Fund | 1.3233 | 1566331 | 1216 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.0409 | 1232035 | 9165 | 2023-07-31 | LOW |
| Candriam Luxembourg S.A. | Investment Advisor | 0.9457 | 1119401 | 14215 | 2023-06-30 | MED |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.853 | 1009582 | -23564 | 2022-12-31 | LOW |
| Biomérieux Employees | Corporation | 0.7268 | 860200 | 0 | 2022-12-13 | |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6229 | 737243 | -2778 | 2023-07-31 | LOW |
| Devon Equity Management Ltd. | Investment Advisor | 0.5669 | 670995 | 0 | 2023-06-30 | LOW |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.5582 | 660731 | 1010 | 2023-07-31 | LOW |
| La Financière de l'Echiquier | Investment Advisor | 0.5558 | 657855 | -52897 | 2023-05-31 | MED |
| DNCA Investments | Investment Advisor | 0.5365 | 635034 | -54254 | 2023-06-30 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.5183 | 613458 | 3315 | 2023-07-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.5121 | 606183 | -2266 | 2023-06-30 | LOW |
| CPR Asset Management | Investment Advisor | 0.4756 | 562920 | -5580 | 2023-06-30 | MED |
| Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.3634 | 430154 | -1 | 2023-06-30 | LOW |
| AXA Investment Managers Paris | Investment Advisor/Hedge Fund | 0.3621 | 428545 | 15038 | 2023-06-30 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.3239 | 383343 | 0 | 2023-06-30 | LOW |
| Zadig Asset Management L.L.P. | Investment Advisor | 0.3042 | 360000 | -180000 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Biomerieux Company profile
About BioMerieux SA
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMerieux SA revenues increased 8% to EUR3.38B. Net income applicable to common stockholders increased 49% to EUR601.1M. Revenues reflect Microbiology segment increase of 12% to EUR1.06B, Molecular Biology segment increase of 5% to EUR1.27B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 10% to EUR1.12B, America segment increase of 5% to EUR1.67B.
Equity composition
9/2017, 3-for-1 stock split (Factor: 3).
| Industry: | Laboratory Diagnostic & Testing Substances |
376, chemin de l'Orme
CRAPONNE
AUVERGNE-RHONE-ALPES 69280
FR
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com